Drug News
For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.
News
In a group of septuagenarian patients with atrial fibrillation, followed for up to six years, warfarin use is associated with a significant reduction in all-cause mortality.
Drug News
For warfarin-treated patients, carbamazepine co-treatment is associated with subtherapeutic anticoagulative effect and increased warfarin dose requirements, according to a study published online in the Journal of Thrombosis and Haemostasis.
News
Treating acute ischemic stroke patients who are warfarin users with tissue plasminogen activator (tPA) does not increase the risk of intracranial hemorrhage (ICH).
AHA 2018
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
News
In the 90 days following a gastrointestinal tract bleeding (GIB) event, patients who do not resume warfarin therapy experience an increased rate of thrombosis and death.
News
Patients who undergo bioprosthetic aortic valve replacement surgery and discontinue anticoagulant treatment within six months have a greater risk of cardiovascular death.
News
Use of warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) is associated with a low risk of stroke or systemic embolism.
Drug News
For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.
News
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
